The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia

Creative Commons License

AKSU S., ŞAHİN F., Uz B., Yavuz S. A., Atay H., KELKİTLİ E., ...More

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.22, no.1, pp.8-14, 2012 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.4999/uhod.12004
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.8-14
  • Hacettepe University Affiliated: Yes


We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.